A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment

scientific article published on 10 October 2013

A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1010922902
P356DOI10.1007/S11523-013-0295-4
P698PubMed publication ID24114566

P2093author name stringAlaaeldin Shablak
Andrew Conn
P2860cites workAssociation of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewQ21198850
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Q27824867
Global cancer statistics, 2002Q27860562
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancerQ28240089
Management and preparedness for infusion and hypersensitivity reactionsQ30229857
Cancer statistics, 2000.Q33895772
Metastatic colorectal cancerQ34677913
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancerQ35857638
Interstitial lung disease in lung cancer: separating disease progression from treatment effects.Q36029824
Pulmonary toxicity from novel antineoplastic agentsQ36314452
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyQ36610301
A rare but severe pulmonary side effect of cetuximab in two patients.Q38030496
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Q38071119
Cetuximab-associated pulmonary toxicityQ43279298
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tabletsQ44535930
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinibQ44936060
Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.Q45997056
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinomaQ46816802
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancerQ46892017
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupQ56562473
P433issue2
P921main subjectcetuximabQ420296
interstitial lung diseaseQ1153419
P304page(s)177-180
P577publication date2013-10-10
P1433published inTargeted oncologyQ25378200
P1476titleA case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment
P478volume9

Reverse relations

cites work (P2860)
Q40812370Adverse events of monoclonal antibodies used for cancer therapy
Q90914261Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck
Q47672858Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective

Search more.